Compare
Mineralys Therapeutics, Inc. vs Protagonist Therapeutics, Inc vs Immunome Inc. vs Nurix Therapeutics, Inc.
| Latest fiscal year | Mineralys Therapeutics, Inc. MLYS | Protagonist Therapeutics, Inc PTGX | Immunome Inc. IMNM | Nurix Therapeutics, Inc. NRIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-11-30 |
| Revenue | n/a | $46.02M | $6.94M | $83.98M |
| Revenue growth (YoY) | n/a | -89.4% | -23.2% | +54.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -343.6% | n/m | -340.2% |
| Net margin | n/a | -282.8% | n/m | -314.9% |
| Net income | -$154.65M | -$130.15M | -$212.39M | -$264.46M |
| EPS (Diluted) | -$2.29 | -$2.05 | -$2.43 | -$3.05 |
| Operating cash flow | -$142.42M | $57.67M | -$190.92M | -$249.47M |
| Free cash flow | -$142.43M | $56.08M | -$200.60M | -$263.47M |
| Cash & equivalents | $172.92M | $128.39M | $653.48M | $246.96M |
| Total assets | $661.81M | $668.19M | $683.19M | $688.13M |
| Total liabilities | n/a | $53.48M | $48.84M | $149.39M |
| Shareholders' equity | $646.69M | $614.71M | $634.34M | $538.75M |
| Return on year-end equity | -23.9% | -21.2% | -33.5% | -49.1% |
| Shares outstanding | 81.54M | 62.58M | 113.13M | 101.81M |
Revenue, most recent five fiscal years
| Fiscal year | Mineralys Therapeutics, Inc. | Protagonist Therapeutics, Inc | Immunome Inc. | Nurix Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $46.02M Ended 2025-12-31 | $6.94M Ended 2025-12-31 | $83.98M Ended 2025-11-30 |
| 1 year earlier | n/a | $434.43M Ended 2024-12-31 | $9.04M Ended 2024-12-31 | $54.55M Ended 2024-11-30 |
| 2 years earlier | n/a | $60.00M Ended 2023-12-31 | $14.02M Ended 2023-12-31 | $76.99M Ended 2023-11-30 |
| 3 years earlier | n/a | $26.58M Ended 2022-12-31 | n/a | $38.63M Ended 2022-11-30 |
| 4 years earlier | n/a | $27.36M Ended 2021-12-31 | n/a | $29.75M Ended 2021-11-30 |